New Novartis AG Chairman Reviews Portfolio, Fueling Speculation That Company May be Splitting Up

Published: Sep 24, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Novartis may take a leaf out of its past deal-book as the Swiss drugmaker conducts a review into some of its underperforming businesses, a board member said.

New chairman Joerg Reinhardt has launched a review of the drugmaker's portfolio fanning speculation that some of the company's smaller units could be sold, spun-off or integrated into other divisions.

Help employers find you! Check out all the jobs and post your resume.

Back to news